Suleiman, Ahmed A <br/><br/>
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.  [electronic resource] 

 -  Clinical pharmacokinetics  03 2019 
 - 375-387 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-1926 
<br/><br/><label>Standard No.: </label>10.1007/s40262-018-0704-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Biological Availability<br/>Biological Variation, Population--drug effects<br/>Body Weight--drug effects<br/>Crohn Disease--blood<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Interleukin-23--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Psoriasis--blood<br/>Serum Albumin--drug effects